S. Kulkarni

发表

Recombinant tissue plasminogen activator (rtPA) for the treatment of hepatic veno-occlusive disease (VOD)

S. Singhal, J. Mehta, D. Tait, 1999, Bone Marrow Transplantation.

Mycophenolic acid trough level monitoring: relevance in acute and chronic graft versus host disease and its relation with albumin

G. Morgan, J. Tredger, F. Davies, 2011, Clinical transplantation.

Chronic graft versus host disease is associated with long-term risk for pneumococcal infections in recipients of bone marrow transplants.

S. Singhal, J. Mehta, B. Sirohi, 2000, Blood.

Evaluation of an immunoturbidimetric D-dimer assay and pretest probability score for suspected venous thromboembolism in a district hospital setting

P. Anoop, S. Kulkarni, P. Chappell, 2009, Hematology.

Long-term outcome of adult acute leukemia patients who are alive and well two years after allogeneic bone marrow transplantation from an HLA-identical sibling.

S. Singhal, J. Mehta, R. Powles, 1999, Leukemia & lymphoma.

Use of physiological doses of human growth hormone in haematological patients receiving intensive chemotherapy promotes haematopoietic recovery: a double-blind randomized, placebo-controlled study

G. Morgan, B. Sirohi, G. Cook, 2007, Bone Marrow Transplantation.

Oral idarubicin as a single agent therapy in patients with relapsed or resistant multiple myeloma.

P. Mainwaring, N. Raje, J. Treleaven, 1999, Leukemia & lymphoma.

Comparison of dexamethasone and metoclopramide as antiemetics in children receiving cancer chemotherapy.

S. Advani, B. Saikia, S. Kulkarni, 1996, Indian pediatrics.

Re-use of the original infusional induction chemotherapy as salvage therapy in myeloma patients relapsing after one autograft

S. Singhal, J. Mehta, B. Sirohi, 2005, Hematology.

Outcome of high-dose cytarabine-based induction therapy followed by hematopoietic stem cell transplantation in acute myeloid leukemia: influence of karyotype

Robin L. Jones, G. Morgan, S. Singhal, 2008, Leukemia & lymphoma.

Impact of cytogenetics on the outcome of autotransplantation for acute myeloid leukemia in first remission: is the benefit of intensive pretransplant therapy limited to patients with good karyotypes?

S. Singhal, J. Mehta, B. Sirohi, 2003, Bone Marrow Transplantation.

Genomic profiling of acute myeloid leukaemia associated with ataxia telangiectasia identifies a complex karyotype with wild‐type TP53 and mutant KRAS, G3BP1 and IL7R

A. Taylor, S. Meyer, A. Larionov, 2020, Pediatric blood & cancer.

Some early phase II trials in previously untreated multiple myeloma: The Royal Marsden experience.

B. Sirohi, R. Powles, S. Kulkarni, 2001, Seminars in hematology.

Collection of peripheral blood stem cells in newly diagnosed myeloma patients without any prior cytoreductive therapy: the first step towards an ‘operational cure’?

S. Singhal, J. Mehta, B. Sirohi, 2000, Bone Marrow Transplantation.

Allogeneic transplantation from HLA-matched sibling or partially HLA-mismatched related donors for primary refractory acute leukemia

S. Singhal, J. Mehta, B. Sirohi, 2002, Bone Marrow Transplantation.

Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: a randomised trial

S. Singhal, J. Mehta, D. Tait, 2000, The Lancet.

Comparison of marrow and blood cell yields from the same donors in a double-blind, randomized study of allogeneic marrow vs blood stem cell transplantation

S. Singhal, J. Mehta, B. Sirohi, 2000, Bone Marrow Transplantation.

Secondary myelodysplastic syndrome/acute myeloid leukaemia following mitoxantrone-based therapy for breast carcinoma

J. Mehta, T. Powles, S. Ashley, 2000, British Journal of Cancer.

Melphalan/TBI is not more carcinogenic than cyclophosphamide/TBI for transplant conditioning: follow-up of 725 patients from a single centre over a period of 26 years

S. Singhal, J. Mehta, D. Tait, 2000, Bone Marrow Transplantation.

Prognostic factors for mortality

M. Dennis, T. Somervaille, J. Cavet, 2022 .

Serum tumor necrosis factor for monitoring response of hepatic veno-occlusive disease to pentoxiphyllin--a case report.

P. Parikh, S. Advani, S. Kulkarni, 1997, Cancer investigation.

Gonadal function following ABVD therapy for Hodgkin's disease.

P. Parikh, S. Advani, S. Kulkarni, 1997, American journal of clinical oncology.

Haploidentical vs autologous hematopoietic stem cell transplantation in patients with acute leukemia beyond first remission

S. Singhal, J. Mehta, B. Sirohi, 2003, Bone Marrow Transplantation.

The role of posttransplantation maintenance chemotherapy in improving the outcome of autotransplantation in adult acute lymphoblastic leukemia.

S. Singhal, J. Mehta, D. Tait, 2002, Blood.

The role of maintenance chemotherapy after autotransplantation for acute lymphoblastic leukemia in first remission: single-center experience of 100 patients

G. Morgan, S. Singhal, J. Mehta, 2008, Bone Marrow Transplantation.

The impact of karyotype on remission rates in adult patients with de novo acute myeloid leukemia receiving high-dose cytarabine-based induction chemotherapy.

S. Singhal, J. Mehta, T. Min, 1999, Leukemia & lymphoma.

Impact of previous high-dose therapy on outcome after allografting for multiple myeloma

S. Singhal, J. Mehta, D. Tait, 1999, Bone Marrow Transplantation.

A low CD34+ cell dose results in higher mortality and poorer survival after blood or marrow stem cell transplantation from HLA-identical siblings: should 2 × 106 CD34+ cells/kg be considered the minimum threshold?

S. Singhal, J. Mehta, D. Tait, 2000, Bone Marrow Transplantation.

Collection of peripheral blood stem cells in new patients with myeloma receiving minimal or no prior cytoreductive therapy

G. Morgan, B. Sirohi, R. Powles, 2007, Hematology.

Long-term follow-up of relapsed acute leukemia treated with immunotherapy after allogeneic transplantation: the inseparability of graft-versus-host disease and graft-versus-leukemia, and the problem of extramedullary relapse.

S. Singhal, J. Mehta, R. Powles, 1999, Leukemia & lymphoma.

High-dose melphalan and autotransplantation followed by post transplant maintenance chemotherapy for acute lymphoblastic leukemia in first remission

S. Singhal, J. Mehta, B. Sirohi, 2004, Bone Marrow Transplantation.

Acute lymphoblastic leukaemia-type intensive chemotherapy to eliminate minimal residual disease after high-dose melphalan and autologous transplantation in multiple myeloma – a phase I/II feasibility and tolerance study of 17 patients

S. Singhal, J. Mehta, N. Raje, 2000, Bone Marrow Transplantation.

Rapid cytoreduction in childhood leukemic hyperleukocytosis by conservative therapy.

S. Pai, P. Kurkure, C. Nair, 1995, Medical and pediatric oncology.

Long-term outcome of adult acute leukemia patients who are alive and well 2 years after autologous blood or marrow transplantation

S. Singhal, J. Mehta, R. Powles, 1999, Bone Marrow Transplantation.

Thalidomide after allogeneic haematopoietic stem cell transplantation: activity in chronic but not in acute graft-versus-host disease

S. Singhal, J. Mehta, B. Sirohi, 2003, Bone Marrow Transplantation.

Acute myeloid leukaemia Does donor-recipient ABO incompatibility protect against relapse after allogeneic bone marrow transplantation in first remission acute myeloid leukemia?

S. Singhal, J. Mehta, D. Tait, 2002 .

Does donor–recipient ABO incompatibility protect against relapse after allogeneic bone marrow transplantation in first remission acute myeloid leukemia?

S. Singhal, J. Mehta, D. Tait, 2002, Bone Marrow Transplantation.

Identification of patients who may benefit from prophylactic immunotherapy after bone marrow transplantation for acute myeloid leukemia on the basis of lymphocyte recovery early after transplantation.

S. Singhal, J. Mehta, R. Powles, 1998, Blood.

Two case reports involving therapeutic monoclonal anti‐CD47 (Hu5F9‐G4), it's effect on compatibility testing and subsequent selection of components for transfusion

J. Eggington, S. Kulkarni, K. Lord, 2020, Transfusion medicine.

Number of nucleated cells infused during allogeneic and autologous bone marrow transplantation: an important modifiable factor influencing outcome.

S. Singhal, J. Mehta, R. Powles, 1997, Blood.

The role of autologous transplantation in patients with multiple myeloma aged 65 years and over

S. Singhal, J. Mehta, H. Pandha, 2000, Bone Marrow Transplantation.

Induction of graft-versus-host disease as immunotherapy of leukemia relapsing after allogeneic transplantation: single-center experience of 32 adult patients

S. Singhal, J. Mehta, R. Powles, 1997, Bone Marrow Transplantation.

The implication of compromised renal function at presentation in myeloma

S. Singhal, J. Mehta, N. Raje, 2001, Medical oncology.

Prognostic factors for mortality with fungal blood stream infections in patients with hematological and non-hematological malignancies

M. Dennis, T. Somervaille, J. Cavet, 2013, South Asian Journal of Cancer.

Reassessing autotransplantation for acute myeloid leukaemia in first remission – a matched pair analysis of autologous marrow vs peripheral blood stem cells

S. Singhal, J. Mehta, M. Labopin, 2004, Bone Marrow Transplantation.

High‐grade transformation in splenic marginal zone lymphoma with circulating villous lymphocytes: the site of transformation influences response to therapy and prognosis

D. Catovsky, A. Wotherspoon, E. Matutes, 2008, British journal of haematology.

Comparison of marrow vs blood-derived stem cells for autografting in previously untreated multiple myeloma.

S. Singhal, J. Mehta, N. Raje, 1997, British Journal of Cancer.

Brentuximab vedotin in refractory CD30+ lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK center

J. Radford, T. Illidge, K. Linton, 2013, Haematologica.

Glomerular filtration rate prior to high-dose melphalan 200 mg/m2as a surrogate marker of outcome in patients with myeloma

S. Singhal, J. Mehta, B. Sirohi, 2001, British Journal of Cancer.

Bone marrow necrosis in APML

P. Parikh, S. Limentani, S. Advani, 1995, American journal of hematology.

Implications for the monitoring of patients with multiple myeloma undergoing treatment with the anti-CD38 monoclonal daratumumab

P. Monaghan, J. Cavet, Sally Thirkettle, 2019, Annals of clinical biochemistry.

Response to induction chemotherapy is not essential to obtain survival benefit from high-dose melphalan and autotransplantation in myeloma

S. Singhal, J. Mehta, B. Sirohi, 2002, Bone Marrow Transplantation.

Complete remission rate and outcome after intensive treatment of 177 patients under 75 years of age with IgG myeloma defining a circumscribed disease entity with a new staging system

S. Singhal, J. Mehta, N. Raje, 1999, British journal of haematology.

An elective single autograft with high-dose melphalan: single-center study of 451 patients

S. Singhal, J. Mehta, B. Sirohi, 2005, Bone Marrow Transplantation.

A comparison of vincristine and doxorubicin infusional chemotherapy with methylprednisolone (VAMP) with the addition of weekly cyclophosphamide (C‐VAMP) as induction treatment followed by autografting in previously untreated myeloma

S. Singhal, J. Mehta, D. Cunningham, 1997, British journal of haematology.

Outcome assessment of a population-based group of 195 unselected myeloma patients under 70 years of age offered intensive treatment

S. Singhal, J. Mehta, M. Gore, 1997, Bone Marrow Transplantation.

An open, randomized, controlled, phase II, single centre, two-period cross-over study to compare the quality of life and toxicity experienced on PEG interferon with interferon-alpha2b in patients with multiple myeloma maintained on a steady dose of interferon-alpha2b.

G. Morgan, A. Leary, B. Sirohi, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Comparison of new patients with Bence-Jones, IgG and IgA myeloma receiving sequential therapy: the need to regard these immunologic subtypes as separate disease entities with specific prognostic criteria

S. Singhal, J. Mehta, B. Sirohi, 2001, Bone Marrow Transplantation.